Phreesia Stock Price, News & Analysis

Phreesia (NYSE: PHR) reported strong Q1 fiscal 2026 results with total revenue reaching $115.9 million, up 15% year-over-year. The company significantly reduced its net loss to $3.9 million from $19.7 million in the previous year. Adjusted EBITDA improved to $20.8 million from $4.1 million year-over-year. The average number of healthcare services clients grew 9% to 4,411, with revenue per client increasing 6% to $26,283. Free cash flow turned positive at $7.5 million compared to negative $6.2 million last year. The company maintains its FY2026 revenue outlook of $472-482 million and raised its Adjusted EBITDA guidance to $85-90 million. With $90.9 million in cash and an unused credit facility, Phreesia appears well-positioned to fund its growth initiatives.

Phreesia (NYSE: PHR) has updated the timing of its fiscal first quarter 2026 financial results release to before market trading on Wednesday, May 28, 2025, instead of after market close as previously announced. The company will host a conference call at 8:30 AM Eastern Time on the same day to discuss the results.

Phreesia, founded in 2005, is a healthcare technology company specializing in patient activation solutions. In 2024, the company facilitated approximately 170 million patient visits, representing 1 in 7 healthcare visits across the United States. The company provides digital solutions for patient intake, outreach, and education to enhance patient experience and healthcare outcomes.

Phreesia (NYSE: PHR) has scheduled the release of its fiscal first quarter 2026 financial results for Wednesday, May 28, 2025, after market close. The company will host a conference call at 5PM Eastern Time on the same day, with dial-in numbers (800) 715-9871 for domestic and (646) 307-1963 for international participants.

Key Details:

• Conference code: 7404611
• Results will be posted on ir.phreesia.com
• Call replay available for approximately 90 days

Company Overview: Founded in 2005, Phreesia is a leader in patient activation solutions for healthcare providers and life sciences companies. In 2024, the platform facilitated approximately 170 million patient visits, representing 1 in 7 healthcare visits across the United States. The company specializes in digital solutions for patient intake, outreach, and education to enhance patient experience and healthcare outcomes.

Phreesia (PHR), a leading patient intake and activation company, has been recognized in G2's 2025 Best Software Awards in the Healthcare Software Products category. This recognition is based on authentic user reviews from G2, the world's largest software marketplace reaching 100 million buyers annually.

The company, which facilitated approximately 170 million patient visits in 2024 (representing 1 in 7 visits across the U.S.), provides digital solutions for healthcare providers focusing on patient intake, outreach, education, and activation. The award selection process utilized G2's proprietary algorithm, considering verified user reviews and market presence data from the 2024 calendar year.

Phreesia (NYSE: PHR) reported its Q4 and fiscal 2025 results, showing continued growth and improved financial performance. Q4 total revenue reached $109.7 million, up 15% year-over-year, while the average number of healthcare services clients increased 10% to 4,341.

The company significantly reduced its net loss to $6.4 million in Q4, compared to $30.6 million in the prior year. Q4 Adjusted EBITDA improved to $16.4 million from negative $3.5 million year-over-year. Cash position remained strong at $84.2 million as of January 31, 2025.

For fiscal 2025, revenue grew 18% to $419.8 million, with net loss improving to $58.5 million from $136.9 million in fiscal 2024. The company maintains its fiscal 2026 outlook with expected revenue between $472-482 million and Adjusted EBITDA of $78-88 million, targeting approximately 4,500 healthcare services clients.

Phreesia's Vice President of Product Management, Sally Thayer, has been named to The Software Report's Top 50 Women Leaders in Software of 2024. This marks the seventh consecutive year a female leader from Phreesia has received this recognition. In her role, Thayer oversees patient engagement applications and manages multiple product teams developing software solutions for healthcare organizations.

With over 20 years of healthcare technology experience, Thayer leads teams responsible for patient registration, communication, clinical documentation, and user experience. Under her leadership, Phreesia enabled approximately 150 million patient visits in 2023, representing more than 1 in 10 visits across the U.S. The company, founded in 2005, specializes in patient intake, outreach, and activation solutions.

Phreesia (NYSE: PHR) has announced it will release its fiscal fourth quarter and fiscal year 2025 financial results after market trading on Wednesday, March 12, 2025. The company will publish a press release and quarterly stakeholder letter on its investor website at ir.phreesia.com, followed by a conference call at 5PM Eastern Time.

Investors can participate in the conference call by dialing (800) 715-9871 (US) or (646) 307-1963 (international) using conference code 7404611. A replay will be available via webcast for approximately 90 days. Founded in 2005, Phreesia is a patient activation platform that facilitated approximately 150 million patient visits in 2023, representing more than 1 in 10 healthcare visits across the U.S.

Phreesia (NYSE: PHR) reported its Q3 FY2025 financial results with total revenue of $106.8 million, up 17% year-over-year. The company's average healthcare services clients (AHSCs) increased 15% to 4,237. Net loss improved to $14.4 million from $31.9 million in the prior year, while Adjusted EBITDA turned positive at $9.8 million compared to negative $6.6 million.

The company narrowed its FY2025 revenue guidance to $418-420 million (17-18% growth) and raised Adjusted EBITDA outlook to $34-36 million. For FY2026, Phreesia projects revenue of $472-482 million and Adjusted EBITDA of $78-88 million, with AHSCs expected to reach approximately 4,500.

Phreesia has been named one of the 'Top 100 Software Companies of 2024' by The Software Report for the third consecutive year, ranking 11th on the list, up four positions from 2023. The selection criteria included product functionality, customer satisfaction, corporate reputation, innovative capabilities, organizational depth, ESG involvement, and long-term viability.

As a leader in patient intake, outreach and activation, Phreesia facilitated approximately 150 million patient visits in 2023, representing more than 1 in 10 healthcare visits across the U.S. The company provides patient-driven digital solutions for intake, outreach, and education to enhance patient experience and improve healthcare outcomes.